Core Viewpoint - Ark Health (06086) has successfully completed a placement and subscription of shares, raising approximately HKD 144.3 million for the development of its AI-driven chronic disease management platform [1] Group 1: Share Placement and Subscription - A total of 45.181 million shares were successfully placed at a price of HKD 3.32 per share to no fewer than six subscribers [1] - The subscription was completed on February 2, 2026, with the same number of shares issued at the same price [1] - The newly issued shares represent approximately 3.26% of the company's enlarged issued share capital [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be used to accelerate the development of the AI-driven chronic disease management platform, including model development, infrastructure expansion, talent acquisition, data collection, and knowledge base development [1] - The remaining 10% of the proceeds will be allocated for working capital and other general corporate purposes [1]

Group 1 - Ark Health (06086.HK) experienced a significant drop, falling over 17% to reach HKD 3.12, with a current decline of 15.82% at the time of reporting [1][7]. - The company announced a placement of 45.181 million shares using a "old shares first, new shares later" method, which represents approximately 3.26% of the company's expanded issued share capital [3][9]. - The placement price is set at HKD 3.32 per share, reflecting a discount of about 11.94% compared to the previous closing price, with expected total proceeds of HKD 150 million and net proceeds of HKD 144 million [3][9]. Group 2 - Approximately 90% of the proceeds will be allocated to accelerate the development of the company's AI-driven chronic disease management platform, including model development and optimization, infrastructure and computing resource expansion, talent acquisition in AI and medical fields, data collection and annotation, knowledge base development, and the launch and promotion of AI-enhanced services to underserved patient and doctor groups [3][9]. - The remaining 10% of the funds will be used for working capital and general corporate purposes [3][9].